4D Molecular Therapeutics... (FDMT)
4.45
-0.08 (-1.77%)
At close: Mar 03, 2025, 11:42 AM
No 1D chart data available
| Bid | 4.44 |
| Market Cap | 205.71M |
| Revenue (ttm) | 14.15K |
| Net Income (ttm) | -119.39M |
| EPS (ttm) | -2.85 |
| PE Ratio (ttm) | -1.56 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 4.46 |
| Volume | 195,024 |
| Avg. Volume (20D) | 915,534 |
| Open | 4.53 |
| Previous Close | 4.53 |
| Day's Range | 4.45 - 4.81 |
| 52-Week Range | 4.20 - 36.25 |
| Beta | 2.79 |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 147
Stock Exchange NASDAQ
Ticker Symbol FDMT
Analyst Forecast
According to 10 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 787.64% from the latest price.
Buy 80.00%
Hold 10.00%
Sell 10.00%
Earnings Surprise
4D Molecular Therapeutics has released their quartely earnings
on Feb 28, 2025:
Next Earnings Release
4D Molecular Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-13.91%
4D Molecular Therapeutics shares are trading lower...
Unlock content with
Pro Subscription
1 month ago
-13.77%
4D Molecular Therapeutics shares are trading lower after Leerink Partners and Morgan Stanley cut their respective price targets on the stock.
